Getty Images
Many estate planners believe that their job is done when the beneficiaries avoid probate and receive their inheritance. However, when beneficiaries receive their inheritance in their name outright, that needlessly exposes the legacy you leave to the claims of creditors,
The July 20 press release from Sundial Growers (NASDAQ:SNDL) announcing that it had closed its purchase of the Spiritleaf retail cannabis network didn’t do anything for SNDL stock.
Source: Postmodern Studio / Shutterstock.com
From July 20 throug
Here's Advertisement
Shares Tesla (NASDAQ:TSLA) slipped Monday morning, falling as much as 3.7%. They have recovered some since, and as of 11:20 a.m. EDT today, shares were down approximately 2%.
The stock’s drop, followed by a partial recovery, seems to coincide with pricing trends of other growth stocks on Monday. Broader-market trends, therefore, are likely the main reason for the stock’s volatility today.
Shares of several electric-vehicle companies closed lower on Thursday, after global auto giant Toyota (NYSE:TM) said that it will cut its September production by 40% due to parts shortages.
Here's how these companies fared on Thursday, relative to their closing prices on Wed
Shares of Globalstar (NYSEMKT:GSAT) rocketed 30% on Wednesday, as rumors of a potential deal with Apple (NASDAQ:AAPL) intensified.
So whatLate last month, respected analyst Ming-Chi Kuo posited that Apple's new iPhones will support satellite communications. Kuo postulat
The U.S. Food and Drug Administration (FDA) approved Comirnaty -- the COVID-19 vaccine co-developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) -- for use in people aged 16 and older on Monday. The news drove shares of Pfizer and BioNTech up 2.5% and 9.6%, respectively. Fell
Shares of Helbiz (NASDAQ:HLBZ) surged on Tuesday after the company announced a streaming partnership with Amazon (NASDAQ:AMZN). By the close of trading, Helbiz's stock price was up 96.6% after soaring as much as 191.6% earlier in the day.
So whatHelbiz has the global dis
Shares of ProQR Inc. (NASDAQ:PRQR), a clinical-stage biopharmaceutical company, soared 28% Thursday morning after announcing a new collaboration deal with Eli Lilly (NYSE:LLY). Excitement for the deal cooled off in the afternoon, and the stock finished the day 12.5% higher.
SoHere's Advertisement